APPLIED GENETIC TECHNOLOGIES CORP Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2021-12-06: Form 8-K; Period of report 2021-11-30; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders; Details 5.02.
- 2021-11-12: Form 8-K/A; Period of report 2021-09-08; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2021-11-09: Form 8-K; Period of report 2021-11-09; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2021-10-14: Form 8-K; Period of report 2021-10-14; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2021-12-06 | 8-K | 2021-11-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 On November 30, 2021, Applied Genetic Technologies Corporation (the “Company”) appointed James Robinson to serve on its board of directors as a Class I director. 5.07 The Company held its 2022 Annual Meeting of Stockholders on November 30, 2021, at which three proposals were submitted to, and approved by, its stockholders. | d419592d8k.htm |
| 2021-11-12 | 8-K/A | 2021-09-08 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On November 9, 2021, in connection with Mr. Lieber’s appointment as the Company’s Chief Financial Officer, the Company entered into an employment agreement with Mr. Lieber, effective as of September 20, 2021 (the “Employment Agreement”). | d237187d8ka.htm |
| 2021-11-09 | 8-K | 2021-11-09 | 2.02 Results of Operations and Financial Condition | 2.02 The information in the press release attached hereto as Exhibit 99.1 is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. | d256113d8k.htm |
| 2021-10-14 | 8-K | 2021-10-14 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On October 14, 2021, Applied Genetic Technologies Corporation (the “Company”) announced the appointment of Susan Schneider, 63, as the Company’s Chief Medical Officer beginning on November 8, 2021. 7.01 On October 14, 2021, the Company issued a press release announcing the appointment of Susan Schneider as the Company’s Chief Medical Officer and Sarah C. DiSalvatore as the Company’s Vice President of Clinical Operations. | d14370d8k.htm |
| 2021-09-23 | 8-K | 2021-09-23 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 7.01 During its earnings call on September 23, 2021, the Company will present a summary of recent corporate and clinical developments. | d232417d8k.htm |
| 2021-09-08 | 8-K | 2021-09-08 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 8, 2021, Applied Genetic Technologies Corporation (the “Company”) announced the appointment of Jonathan I. Lieber, 52, as the Company’s Chief Financial Officer beginning on September 20, 2021. | d205453d8k.htm |
| 2021-08-18 | 8-K | 2021-08-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 16, 2021, Applied Genetic Technologies Corporation (the “Company”) appointed Yehia Hashad to serve on its board of directors as a Class II director. | d186701d8k.htm |
| 2021-07-30 | 8-K | 2021-07-27 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 27, 2021, the compensation committee of our board of directors (and with respect to our Chief Executive Officer, the independent members of our board of directors) approved bonus payments for fiscal year 2021 and salary changes for fiscal year 2022 for our current executive officers. | d205792d8k.htm |
| 2021-06-24 | 8-K | 2021-06-24 | 8.01 Other Events | 8.01 On June 24, 2021, Applied Genetic Technologies Corporation issued a press release reporting 12-month data from its ongoing phase 1/2 Achromatopsia (ACHM) clinical trials. | d175382d8k.htm |
| 2021-06-21 | 8-K | 2021-06-17 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 17, 2021, the compensation committee of the board of directors of Applied Genetic Technologies Corporation (the “Company”) approved additional compensation to be provided to Stephen W. Potter, the Company’s Chief Business Officer, pursuant to a First Amendment to Employment Agreement with Mr. Potter (the “Amendment”). | d173515d8k.htm |
| 2021-05-17 | 8-K | 2021-05-17 | 2.02 Results of Operations and Financial Condition | 2.02 The information in the press release attached hereto as Exhibit 99.1 is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. | d62587d8k.htm |
| 2021-05-06 | 8-K | 2021-05-06 | 8.01 Other Events | 8.01 On May 6, 2021, the Company issued a press release announcing twelve and twenty-four month data from certain dosing groups in its ongoing X-linked retinitis pigmentosa (XLRP) phase 1/2 clinical trial. | d418940d8k.htm |
| 2021-04-26 | 8-K | 2021-04-20 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 20, 2021, Mark S. Shearman notified Applied Genetic Technologies Corporation (the “Company”) of his resignation as chief scientific officer of the Company, effective immediately. | d60411d8k.htm |
| 2021-04-02 | 8-K | 2021-04-02 | 8.01 Other Events | 8.01 On April 2, 2021, Applied Genetic Technologies Corporation (the “Company”) entered into a Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”) to sell shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), from time to time, through an “at the market offering” program having an aggregate offering price of up to $50,000,000, through which Cantor will act as sales agent (the “Sales Agent”). | d154428d8k.htm |
| 2021-02-11 | 8-K | 2021-02-11 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 7.01 The Company will present during its earnings call on February 11, 2021 a summary of recent corporate and clinical developments. | d102227d8k.htm |
| 2021-02-01 | 8-K | 2021-02-01 | 7.01 Regulation FD Disclosure | 7.01 Applied Genetic Technologies Corporation (the “Company”) has posted an update to its corporate presentation (the “Corporate Presentation”) on its website. | d121624d8k.htm |
| 2021-01-29 | 8-K | 2021-01-28 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into Material Definitive Agreement. 8.01 On January 27, 2021, the Company issued a press release announcing the commencement of the Offering. | d29000d8k.htm |
| 2021-01-27 | 8-K | 2021-01-27 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 8.01 Other Events | 2.02 Applied Genetic Technologies Corporation (the “Company”) is disclosing that its cash, cash equivalents and investments as of December 31, 2020 was approximately $53.1 million. 7.01 On January 27, 2021, the Company issued a press release announcing updated information regarding its ongoing Achromatopsia (ACHM) clinical trials. 8.01 On January 27, 2021, the Company reported results in from its ACHMB3 and ACHMA3 clinical trials. | d118119d8k.htm |